Mumbai, India – GNH India, a leading WHO cGSDP-certified pharmaceutical wholesaler, made a significant impact at the 9th Biosimilars Congregation 2016, held on September 22, 2016, at The Lalit Hotel in Mumbai. The event, organized by Virtue Insight, brought together top pharmaceutical, biotechnology, and regulatory experts to discuss the evolving landscape of biosimilars, and GNH India emerged as a key player in showcasing India’s potential in the global biosimilars market.

The 9th Biosimilars Congregation focused on critical topics such as regulatory frameworks, biosimilar development, and commercialization strategies. Dr. Piyush Gupta, Associate Director of Business Development at GNH India, delivered a compelling presentation on the company’s expertise in comparator sourcing and the role of India’s biosimilar ecosystem in addressing global healthcare needs. With India leading the world with nearly 100 approved biosimilars, GNH India highlighted its robust supply chain and quality management systems, which ensure compliance with international standards while offering cost-effective solutions.

“India is at the forefront of the biosimilars revolution, and GNH India is proud to lead the charge in providing high-quality, affordable comparators and biosimilars to support global clinical trials,” said Dr. Gupta during his address.

GNH India’s participation underscored its decade-long experience in clinical trial supplies, including biologics and biosimilars, with a network spanning over 180 countries and a portfolio of more than 135,000 product lines. The company’s WHO cGSDP-certified facilities in Mumbai and adherence to GDP, GxP, and ISO standards were highlighted as key differentiators, enabling GNH India to meet the stringent demands of global biopharmaceutical companies.

The conference also addressed challenges in biosimilar development, such as regulatory hurdles and the need for robust comparability studies. GNH India showcased its ability to navigate these complexities, offering smart sourcing solutions that reduce costs by up to 50% compared to traditional markets, while maintaining the highest standards of safety and efficacy. The event provided a platform for GNH India to forge new partnerships and explore opportunities to expand its global footprint in the biosimilars sector.

“Our goal is to make life-saving treatments accessible by leveraging India’s biosimilar expertise. Events like the Biosimilars Congregation allow us to collaborate with industry leaders and drive innovation,” Dr. Gupta added.

The 9th Biosimilars Congregation 2016 highlighted the immense potential of India’s biosimilar market, projected to reach $12 billion by 2025. GNH India’s contributions to the event reinforced its position as a trusted partner in the biopharmaceutical industry, committed to delivering quality and affordability to patients worldwide.